🔵 RESEARCH
Trial tests AI for anesthesiologist-read gastric POCUS
An observational study will train and test an AI tool to help anesthesiologists classify stomachs as full or empty on point-of-care ultrasound.
Aspiration risk assessment is a high-stakes, low-volume skill for many anesthesiologists. If validated, AI-assisted gastric POCUS opens a procedural workflow niche that software-first vendors could lock in before ultrasound OEMs bundle equivalent capability.
🔵 RESEARCH
Multicenter trial tests ED POCUS to rule out small bowel obstruction
A multicenter diagnostic study evaluates emergency physician point-of-care ultrasound for ruling out small bowel obstruction, currently diagnosed by abdominal CT.
A positive readout would chip away at CT volumes in the ED and accelerate POCUS adoption into yet another abdominal indication. Watch for sensitivity and negative predictive value against CT before reading anything into workflow impact.
🔴 REGULATORY
Artera clears FDA for AI breast cancer risk prediction tool
Artera, which launched in 2023 with $90 million in funding, received FDA clearance for its AI breast cancer risk prediction tool.
Artera now competes directly with Volpara and iCAD in risk stratification, where premium pricing beats detection-only AI. Clearance strengthens fundraising posture, but real-world screening impact still requires prospective outcomes data.
🔴 REGULATORY
HistoSonics seeks FDA de novo for kidney cancer histotripsy
HistoSonics, backed by Bezos Expeditions and Thiel Bio in a $250M round, is pursuing de novo FDA authorization for ultrasound-based kidney cancer ablation.
A de novo pathway would establish HistoSonics as the predicate for histotripsy competitors and validate a minimally invasive oncology asset that larger medtechs may want to acquire. Health systems will gate adoption on CPT codes and procedural volume.
⚪ INDUSTRY
GE HealthCare profiled as precision imaging leader
A market piece positions GE HealthCare as a leader in precision health imaging, without naming specific catalysts or financial metrics.
Generic positioning coverage offers little for investors absent earnings or product specifics. Worth watching against the backdrop of Siemens' aggressive interventional AI clearances this week — competitive pressure on GE's imaging franchise is intensifying.
Google News: POCUS point-of-care ultrasound · Wed, 13 Ma
Read more →
🔴 REGULATORY
FDA clears six Siemens AI interventional imaging platforms
Siemens Healthineers secured FDA clearance for six AI-powered interventional imaging platforms in a single regulatory push.
Siemens is fortifying interventional imaging — a high-margin procedural space — before pure-play AI vendors can plant flags. Expect retaliatory portfolio rollouts from GE HealthCare and Philips, and watch which health systems convert clearances into installations.
Google News: site:diagnosticimaging.com · Tue, 12 Ma
Read more →
🔵 RESEARCH
Multicenter study validates internist-performed POCUS for atrial fibrillation
A 35-site cross-sectional study found internist-performed point-of-care ultrasound delivered high diagnostic accuracy and clinical impact in atrial fibrillation assessment.
Internal medicine is the next frontier for handheld ultrasound adoption, expanding the addressable market for Butterfly, Vscan, and similar devices. Operational uptake hinges on residency curricula and credentialing — the perennial POCUS bottleneck.
Internal and emergency medicine · 2026-05-12
Read more →
🔵 RESEARCH
NLP method extracts mitral valve disease severity from echo reports
Researchers built a text-based classifier to pull mitral valve disease severity from free-text echocardiography reports for secondary data use.
Retrospective mining of echo archives is cheaper than structured reporting reform and could feed registries, quality metrics, and AI training sets. Real value comes if Philips, GE, or EHR vendors embed the classifier into reporting workflows.
Studies in health technology and informatics · 2026-5-12
Read more →
🩺 EDITOR’S TAKE — FOR CLINICIANS
POCUS keeps eating diagnostic territory — gastric content, small bowel obstruction, atrial fibrillation. Imaging specialists should expect more cross-specialty scanning at the bedside and prepare to own credentialing, QA, and image archival rather than gatekeep the probe.
📊 EDITOR’S TAKE — FOR INVESTORS
Incumbents are weaponising regulatory volume: Siemens cleared six interventional AI platforms in one stroke, and Artera joins the breast risk fight against Volpara and iCAD. Pure-play AI valuations need a defensibility story beyond 510(k) count.
🏭 EDITOR’S TAKE — FOR INDUSTRY
Capital is rotating toward therapeutic ultrasound (HistoSonics de novo) and bundled AI portfolios on installed bases. Health systems face a procurement squeeze — single-indication histotripsy suites on one side, ecosystem-wide AI refreshes on the other, both demanding training and workflow rebuilds.